[Clinical and statistical study of the use of alpha-MPG in the treatment of viral hepatitis].
Several workers have already employed alpha-MPG in the management of acute vital hepatitis as a sulphydrylating agent to combat viral poisoning of the liver cells. Its distinct features include the stability of its molecule, its biochemical attributes in the course of time, and its virtually similar oral and injectable LD(50) (2100 MG/KG). High doses, well above those possible with earlier sulphydrylating agents, were used in a trial of alpha-MPG against UDPG. The new drug proved more active and led to a particularly significant fall in SGPT. Subjective and biohumoral parameters returned to normal more quickly, though the differences were not significant. Tolerance was good. Subjective over-reaction with a slight rise in temperature and allergic exanthema was noted in 3 cases. This promptly regressed when the treatment was suspended.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000603:Amino Acids, Sulfur / Q000627:therapeutic use*; D004341:Drug Evaluation; D006525:Hepatitis, Viral, Human / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008625:Tiopronin / Q000627:therapeutic use*
D000603:Amino Acids, Sulfur; D008625:Tiopronin
Studio clinico e statistico sull'impiego di alpha-MPG nel trattamento dell'epatite virale.